SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jayhawk969 who wrote (7383)2/28/2004 4:05:45 PM
From: Rocky9  Read Replies (2) of 10280
 
I go the other direction.

Approval make sale of the company LESS likely. I think that the stock will go too high to be attractive to another company - at least until it turns profitable (still aways away). Plus management has been pointing to the day that it will be a real company. By hiring all the sales people, it will be adding huge overhead, and make it a very expensive proposition for a prospective buyer.

If approval had not come, the company is a one-product company (counting the MDI with Xopenex). The stock would have hammered, and management would have had little or no flexibility with R&D. It would have sold.

Of course, only time will tell. I sure hope that I am right that the market will price it as too expensive.

JMO.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News